The 3 most recent market catalysts affecting $FDMT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 65
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Cantor Fitzgerald's upgrade of 4D Molecular Therapeutics (FDMT) from Neutral to Overweight, coupled with a new $20 price target, indicates a more bullish outlook from a prominent f…
Jul 31, 2026
Corporate Catalyst
Neutral
Impact 65
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37
B. Riley Securities analyst Mayank Mamtani initiated coverage on 4D Molecular Therapeutics (FDMT) with a 'Buy' rating and a $37 price target. This event is significant as new analy…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 85
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
4D Molecular Therapeutics (FDMT) released compelling two-year data for its 4D-150 therapy in wet AMD, demonstrating a substantial 78% reduction in treatment burden compared to stan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.